Optimizing gamma/delta CAR-T therapy for bone-ed metastatic prostate cancer

Who could benefit from this research

What this research studies

This project builds on prior work to enhance a personalized immunotherapy for bone-metastatic castration-resistant prostate cancer. It uses autologous gamma-delta enriched CAR-T cells, combined with the drug zoledronate to boost the immune response in the bone environment. The team plans to study how these CAR-T cells behave in people and how to time treatments to minimize side effects while maximizing anti-tumor activity. They will also analyze clinical samples from patients to better understand Vδ2 T cells and refine the therapy. The ultimate goal is to translate insights from patient samples into improved treatment strategies for individuals with this difficult-to-treat cancer.

Why it matters

Where this research is happening

• H. Lee Moffitt Cancer Ctr & Res Inst
  Tampa, United States Active

Researchers

• Principal investigator: Abate-Daga, Daniel — H. Lee Moffitt Cancer Ctr & Res Inst
• Study coordinator: Abate-Daga, Daniel

Related research

Other NIH-funded projects on the same topics.

• Understanding how aggressive cell states emerge in castration-resistant prostate cancer

  A research project aims to uncover the hidden cell states that help prostate cancer resist standard therapy and how these states arise early in tumor development.

  NIH research State University New York Stony Brook · Stony Brook, United States · NIH-11463275

• Enhancer RNA CYP11A1-eRNA in castration-resistant prostate cancer

  Researchers are testing a new RNA-based target, CYP11A1-eRNA, to see if blocking it can hamper the growth of castration-resistant prostate cancer in the lab and animal models.

  NIH research University of Maryland Baltimore · Baltimore, United States · NIH-11452128

• Targeted Immunostimulatory Dual Drug Conjugates for Heterogeneous Metastatic Prostate Cancer

  Researchers are testing a targeted therapy approach to help people with metastatic castration-resistant prostate cancer by boosting the immune system and delivering drugs directly to cancer cells.

  NIH research University of Wisconsin-Madison · Madison, United States · NIH-11427360

• Androgen Receptor Action in Prostate Cancer that Stops Responding to Therapy

  This grant supports research to understand why certain prostate cancers stop responding to AR-targeted therapies and to find new ways to target them.

  NIH research Beth Israel Deaconess Medical Center · Boston, United States · NIH-11419184

• Modulating Androgen Signals to Boost CAR T Therapy for Prostate Cancer

  A new approach uses CAR T cells targeting STEAP1 to treat advanced prostate cancer, with a focus on how androgen signals affect treatment effectiveness.

  NIH research Fred Hutchinson Cancer Center · Seattle, United States · NIH-11415651

• Hyperactive methylation in a hard-to-treat prostate cancer subtype

  Researchers are studying a newly identified methylation-heavy group of advanced prostate cancer to understand its biology and find clues for better treatments.

  NIH research University of California, San Francisco · San Francisco, United States · NIH-11415138

About this research

1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.